RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Hunan Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05940532, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Other malignant tumors other than non-small cell lung cancer within 5 years before screening;

    Exclusion criterion 9

    Positive HIV test;

    Exclusion criterion 15

    Evidence of active tuberculosis infection within 1 year before the first dose;

    Exclusion criterion 17

  3. Female subjects who are pregnant, lactating, or planning to get pregnant during the study period;

    Exclusion criterion 24

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05940532, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

1.18 to 75 years old, both male and female;

2.ECOG score: 0-1;

3.Histopathologically or cytologically confirmed, stage III (AJCC 8th) non-small cell lung cancer;

4.Multidisciplinary team (MDT) discussion confirmed unresectable disease but can be treated by curative radiotherapy;

5.Measurable lesions available;

6.Major organ function is basically normal;

7.Estimated survival time is at least 6 months;

8.Non-surgically sterile female subjects of childbearing age must have a negative serum HCG test before inclusion.

Exclusion Criteria:

  • Histologically or cytologically confirmed mixed SCLC and NSCLC;
  • Subjects with driver gene mutations(EGFR mutation, ALK fusion, etc.);
  • Previous systemic anti-tumor therapy including immune checkpoint inhibitors for NSCLC;
  • Previous thoracic radiotherapy;
  • Subjects who participated in other clinical trials within 4 weeks or 5 drug half-lives(whichever is shorter) before the first dose;
  • Systemic immunostimulant therapy before the first dose;
  • Systemic immunosuppressive therapy before the first dose or were expected to require systemic immunosuppressive drugs during the study treatment;
  • Subjects with autoimmune diseases;
  • Other malignant tumors other than non-small cell lung cancer within 5 years before screening;
  • Known or suspected interstitial pneumonia;
  • Other moderate to severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity and seriously affect respiratory function;
  • Severe cardiovascular and cerebrovascular diseases;
  • Clinically significant bleeding symptoms or significant bleeding tendency within 1 month before the first dose;
  • Arteriovenous thrombotic events within 3 months before the first dose;
  • Positive HIV test;
  • Active hepatitis B or C;
  • Evidence of active tuberculosis infection within 1 year before the first dose;
  • Serious infection within 4 weeks before the first dose;
  • History of attenuated live vaccination 28 days before the first dose or expected to receive attenuated live vaccination during the study;
  • Major surgeries other than diagnosis or biopsy within 28 days prior to the first dose;
  • Previous or planned allogeneic bone marrow transplantation or solid organ transplantation;
  • History of severe allergic reactions to other monoclonal antibodies/fusion proteins;
  • Allergic to any component of the randomized treatment regimen;
  • Female subjects who are pregnant, lactating, or planning to get pregnant during the study period;
  • Subjects who have a known history of psychotropic drug abuse, alcoholism, or drug abuse;
  • Presence of other conditions that, in the opinion of the investigator, would make participation in this clinical trial inappropriate.

Quoted from ClinicalTrials.gov, NCT05940532, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05940532, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05940532